Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 96

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 96
---
benchmark comparisons were drawn from conventional small molecules and their nanoparticle/liposomal counterparts:

| Drug        |     |          Form |     | Cost per Unit       |     | Price Fold Increase           
 (Liposomal vs. Non-liposomal) |
| Paclitaxel  |     |        $13.54 |     | Abraxane: $1,658.83 |     | ~120x                         |
| Doxorubicin |     | $14.29–$17.78 |     | Doxil: $387–$823    |     | ~27x                          |

| - | Gemzar/Nab-PTX (combo 
 PPPM): ~$8,993 [2]    |

| - | ARB (Candesartan,    
 oral PPPM): ~$74 [3] |

| - | Liposomal-ARB IV (estimated                                                  
 PPPM): $3,700–$7,400 assumed 50–100x increase typical for liposomal oncology 
 agents                                                                       |

Assuming minimum efficacy threshold is proven by future clinical
study as an added 3-month survival benefit (e.g., increasing median OS from ~8.5 to ~11.5 months), which would support regulatory approval
under FDA’s accelerated approval or EMA’s conditional approval pathways.

Epidemiology and Market Size

U.S. incidence of Pancreatic Cancer: ~61,000 new cases per year
[4]

Global incidence: ~495,000 cases annually [5]

Revenue Estimate (U.S. Market Only):

PPPM: $3,700–$7,400

Average duration (based on 3–4 months of use): 3.5 months

Per-patient course cost: $12,950 downside case scenario –
$25,900 upside case scenario

U.S. TAM (61,000 patients/year): ~$790 million to $1.58 billion/year
downside and upside case scenario respectively

Global Revenue Potential:

Global TAM assumed at roughly 4 times the size of the U.S. market
at around $690 million.:

$3.2 billion downside case scenario

$25,900 × 495,000 = ~$6.3 billion upside case scenario

At ~50% market penetration, projected U.S.
revenue can potentially reach ~$390 – $790 million annually, reflecting the premium pricing typical of targeted liposomal oncology
therapeutics and the severity of disease.